Biontech to present new clinical data from first-in-class car-t program bnt211 in late-breaking session at 36th sitc annual meeting

Mainz, germany, november 1, 2021 (globe newswire) --  biontech se (nasdaq: bntx, “biontech” or “the company”), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today announced that new clinical data from the first-in-human phase 1/2 trial evaluating the company's novel car-t cell therapy candidate, bnt211, will be presented in an oral presentation. the presentation is scheduled for the late-breaking abstract poster session at the 36th annual meeting of the society for immunotherapy of cancer (sitc), being held both in person and virtually from november 10 - 14, 2021.
BNTX Ratings Summary
BNTX Quant Ranking